Addex Therapeutics (ADXN) Income towards Parent Company (2022 - 2025)
Historic Income towards Parent Company for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to $142225.5.
- Addex Therapeutics' Income towards Parent Company fell 9910.28% to $142225.5 in Q2 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year decrease of 11362.94%. This contributed to the annual value of $2.6 million for FY2024, which is 12538.75% up from last year.
- Per Addex Therapeutics' latest filing, its Income towards Parent Company stood at $142225.5 for Q2 2025, which was down 9910.28% from -$1.6 million recorded in Q1 2025.
- Addex Therapeutics' Income towards Parent Company's 5-year high stood at $15.9 million during Q2 2024, with a 5-year trough of -$11.1 million in Q4 2024.
- In the last 4 years, Addex Therapeutics' Income towards Parent Company had a median value of -$2.3 million in 2023 and averaged -$2.4 million.
- In the last 5 years, Addex Therapeutics' Income towards Parent Company plummeted by 79604.48% in 2023 and then soared by 76178.03% in 2024.
- Addex Therapeutics' Income towards Parent Company (Quarter) stood at $1.5 million in 2022, then plummeted by 796.04% to -$10.4 million in 2023, then fell by 6.67% to -$11.1 million in 2024, then soared by 101.29% to $142225.5 in 2025.
- Its Income towards Parent Company was $142225.5 in Q2 2025, compared to -$1.6 million in Q1 2025 and -$11.1 million in Q4 2024.